Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Curis, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

5 OF 8 PATIENTS (62.5%) ACHIEVED UNDETECTABLE MRD (UMRD) LEXINGTON, MASS. , DEC. 9, 2025 /PRNEWSWIRE/ -- CURIS, INC. (NASDAQ: CRIS), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF EMAVUSERTIB (CA-4948), AN ORALLY AVAILABLE, SMALL MOLECULE IRAK4 AND FLT3 INHIBITOR, YESTERDAY PROVIDED UPDATED CLINICAL DATA FROM THE ONGOING FRONTLINE ACUTE MYELOID LEUKEMIA (AML) TRIPLET STUDY (CA-4948-104) IN A POSTER PRESENTATION AT THE 67TH ASH ANNUAL MEETING (ASH).

CURIS PROVIDES UPDATED DATA FROM ITS FRONTLINE AML TRIPLET STUDY

LEXINGTON, MASS. , NOV. 14, 2025 /PRNEWSWIRE/ -- CURIS, INC. (NASDAQ: CRIS), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF EMAVUSERTIB (CA-4948), AN ORALLY AVAILABLE, SMALL MOLECULE IRAK4 INHIBITOR, TODAY ANNOUNCED THAT CURIS WILL REPORT EMAVUSERTIB AND BTKI CLINICAL DATA IN PRIMARY CNS LYMPHOMA (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL) IN THREE PRESENTATIONS AND PRECLINICAL DATA ON EMAVUSERTIB IN AN ORAL PRESENTATION AT THE 30TH ANNUAL MEETING OF THE SOCIETY FOR NEURO-ONCOLOGY (SNO) ON NOVEMBER 19-23: NOVEMBER 21, 2025  4:30 PM ET (11:30 AM HT) FORMAT:   POSTER PRESENTATION PRESENTER:  DR. CHRISTIANGROMMES, MEMORIAL SLOAN KETTERING CANCER CENTER, NY, NY TITLE: ANALYSIS OF GENETIC MUTATION PROFILE AND CNS PHARMACOKINETICS IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA PATIENTS RESPONDING TO NOVEL EMAVUSERTIB (IRAK4I) AND BTKI COMBINATION FORMAT:   POSTER PRESENTATION PRESENTER:  DR.LAKSHMI NAYAK, DANA-FARBER CANCER INSTITUTE, BOSTON, MA TITLE:       PRELIMINARY SAFETY AND EFFICACY OFEMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS NOVEMBER 22, 2025  4:45 PM ET (11:45 AM HT) FORMAT:   RAPID ORAL PRESENTATION PRESENTER:  DR. CHRISTIANGROMMES, MEMORIAL SLOAN KETTERING CANCER CENTER, NY, NY TITLE: ANALYSIS OF GENETIC MUTATION PROFILE AND CNS PHARMACOKINETICS IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA PATIENTS RESPONDING TO NOVEL EMAVUSERTIB (IRAK4I) AND BTKI COMBINATION FORMAT:    POSTER PRESENTATION PRESENTER:  CECILIA A.

CURIS TO PRESENT AT UPCOMING 30TH ANNUAL SNO MEETING

MANAGEMENT TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. ET LEXINGTON, MASS.

CURIS PROVIDES THIRD QUARTER 2025 BUSINESS UPDATE

LEXINGTON, MASS. , OCT. 30, 2025 /PRNEWSWIRE/ -- CURIS, INC. (NASDAQ: CRIS), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF EMAVUSERTIB (CA-4948), AN ORALLY AVAILABLE, SMALL MOLECULE IRAK4 INHIBITOR, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT ITS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS ON THURSDAY, NOVEMBER 6, 2025, AT 4:00 P.M.

CURIS TO REPORT THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON NOVEMBER 6, 2025

LEXINGTON, MASS. , OCT. 3, 2025 /PRNEWSWIRE/ --CURIS, INC. (NASDAQ: CRIS), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF EMAVUSERTIB (CA-4948), AN ORALLY AVAILABLE, SMALL MOLECULE IRAK4 INHIBITOR, TODAY ANNOUNCED THAT ON OCTOBER 1, 2025, THE INDEPENDENT COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF CURIS APPROVED THE GRANT OF INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 84,750 SHARES OF CURIS COMMON STOCK TO TWO NEW EMPLOYEES, WITH A GRANT DATE OF OCTOBER 1, 2025 (THE "Q4 2025 INDUCEMENT GRANTS").

CURIS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

LEXINGTON, MASS. , SEPT. 2, 2025 /PRNEWSWIRE/ -- CURIS, INC. (NASDAQ: CRIS), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF EMAVUSERTIB (CA-4948), AN ORALLY AVAILABLE, SMALL MOLECULE IRAK4 INHIBITOR, TODAY ANNOUNCED THAT JAMES DENTZER, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF CURIS, WILL PARTICIPATE AT THE FOLLOWING CONFERENCES: THE CANTOR GLOBAL HEALTHCARE CONFERENCE 2025 BEING HELD SEPTEMBER 3  5, 2025.

CURIS TO PRESENT AT UPCOMING HEALTHCARE CONFERENCES IN SEPTEMBER

MANAGEMENT TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 8:30 A.M. ET LEXINGTON, MASS.

CURIS PROVIDES SECOND QUARTER 2025 BUSINESS UPDATE

LEXINGTON, MASS. , JULY 29, 2025 /PRNEWSWIRE/ -- CURIS, INC. (NASDAQ: CRIS), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF EMAVUSERTIB (CA-4948), AN ORALLY AVAILABLE, SMALL MOLECULE IRAK4 INHIBITOR, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT ITS SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS ON TUESDAY, AUGUST 5, 2025, AT 8:00 A.M.

CURIS TO REPORT SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON AUGUST 5, 2025

LEXINGTON, MASS. , JULY 2, 2025 /PRNEWSWIRE/ -- CURIS, INC. ("CURIS") (NASDAQ: CRIS), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF EMAVUSERTIB (CA-4948), AN ORALLY AVAILABLE, SMALL MOLECULE IRAK4 INHIBITOR, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE AGREEMENT WITH A COMBINATION OF EXISTING AND NEW INVESTORS FOR THE PURCHASE OF 1,538,460 SHARES ("SHARES") OF ITS COMMON STOCK IN A REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES.

CURIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT AND CONCURRENT PRIVATE PLACEMENT

LEXINGTON, MASS. , MAY 6, 2025 /PRNEWSWIRE/ --CURIS, INC. (NASDAQ: CRIS), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF EMAVUSERTIB (CA-4948), AN ORALLY AVAILABLE, SMALL MOLECULE IRAK4 INHIBITOR, TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS OF CURIS APPROVED THE GRANT OF INDUCEMENT STOCK OPTIONS TO ITS NEWLY APPOINTED CHIEF MEDICAL OFFICER, DR. AHMED HAMDY TO PURCHASE 200,000 SHARES OF CURIS COMMON STOCK, WITH A GRANT DATE OF MAY 1, 2025 (THE "INDUCEMENT GRANT").

Curis, Inc.

CRIS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Curis, Inc.

CRIS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CRIS